SP-A enhances viral clearance and inhibits inflammation after pulmonary adenoviral infection.

Surfactant protein A (SP-A) is a member of the collectin family of host defense molecules expressed primarily in the epithelial cells of the lung. To determine the role of SP-A in pulmonary adenoviral infection, SP-A-deficient (SP-A -/-) mice were intratracheally infected with a replication-deficient recombinant adenovirus, Av1Luc1. Lung inflammation was markedly increased in SP-A -/- compared with SP-A +/+ mice and was associated with increased hemorrhage and epithelial cell injury. Polymorphonuclear cells in bronchoalveolar lavage fluid (BALF) were increased in SP-A -/- mice after administration of adenovirus. Coadministration of adenovirus and purified human SP-A ameliorated adenoviral-induced lung inflammation in SP-A -/- mice. Concentrations of tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, and IL-1beta were increased in BALF of SP-A -/- mice. Likewise, TNF-alpha, IL-6, macrophage inflammatory protein (MIP)-1alpha, monocyte chemotactic protein-1, and MIP-2 mRNAs were increased in lung homogenates from SP-A -/- mice 6 and 24 h after viral administration. Clearance of adenoviral DNA from the lung and uptake of fluorescent-labeled adenovirus by alveolar macrophages were decreased in SP-A -/- mice. SP-A enhances viral clearance and inhibits lung inflammation during pulmonary adenoviral infection, providing support for the importance of SP-A in antiviral host defense.

[1]  B. Trapnell,et al.  Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. , 1998, Human gene therapy.

[2]  V. Shepherd,et al.  Surfactant protein A inhibits T cell proliferation via its collagen-like tail and a 210-kDa receptor. , 1998, The American journal of physiology.

[3]  J. Whitsett,et al.  Surfactant protein-A-deficient mice are susceptible to Pseudomonas aeruginosa infection. , 1998, American journal of respiratory cell and molecular biology.

[4]  N. Hackett,et al.  Fluorescent virions: dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells. , 1998, Human gene therapy.

[5]  B. Stripp,et al.  Clara cell secretory protein decreases lung inflammation after acute virus infection , 1998 .

[6]  G. Wolff,et al.  Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. , 1997, Human gene therapy.

[7]  J. Whitsett,et al.  Surfactant protein A-deficient mice are susceptible to group B streptococcal infection. , 1997, Journal of immunology.

[8]  B. Benaissa-Trouw,et al.  Surfactant protein A, but not surfactant protein D, is an opsonin for influenza A virus phagocytosis by rat alveolar macrophages , 1997, European journal of immunology.

[9]  M. Finegold,et al.  Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo , 1997, Gene Therapy.

[10]  A. Jobe,et al.  Surfactant metabolism in surfactant protein A-deficient mice. , 1997, The American journal of physiology.

[11]  B. Harvey,et al.  Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ , 1997, Journal of virology.

[12]  B. Stripp,et al.  Altered surfactant function and structure in SP-A gene targeted mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Wright,et al.  Surfactant protein A protects growing cells and reduces TNF-alpha activity from LPS-stimulated macrophages. , 1996, The American journal of physiology.

[14]  M. Pollack,et al.  Surfactant content in children with inflammatory lung disease. , 1996, Critical care medicine.

[15]  J. Whitsett,et al.  Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. , 1995, Human gene therapy.

[16]  H. Ertl,et al.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses , 1995, Journal of virology.

[17]  N. Sarvetnick,et al.  Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Harmsen,et al.  Interactions of surfactant protein A with influenza A viruses: binding and neutralization. , 1995, The Journal of infectious diseases.

[19]  J. Coonrod,et al.  Aggregation and opsonization of type A but not type B Hemophilus influenzae by surfactant protein A. , 1994, American journal of respiratory cell and molecular biology.

[20]  E. Furth,et al.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Wright,et al.  Pulmonary surfactant protein A stimulates chemotaxis of alveolar macrophage. , 1993, The American journal of physiology.

[22]  J. Whitsett,et al.  Decreased surfactant protein A in patients with bacterial pneumonia. , 1993, The American review of respiratory disease.

[23]  C. Sidman,et al.  Differential cytokine expression in acute and chronic murine graft‐versus‐host‐disease , 1993, European journal of immunology.

[24]  R. Ezekowitz,et al.  Collectins: pattern recognition molecules involved in first line host defense. , 1993, Current opinion in immunology.

[25]  J. Verhoef,et al.  Binding of surfactant protein A (SP-A) to herpes simplex virus type 1-infected cells is mediated by the carbohydrate moiety of SP-A. , 1992, The Journal of biological chemistry.

[26]  W. Seeger,et al.  Surfactant protein A (SP‐A) is decreased in acute parenchymal lung injury associated with polytrauma * , 1992, European journal of clinical investigation.

[27]  J. Wright,et al.  Specific binding of surfactant apoprotein SP-A to rat alveolar macrophages. , 1992, The American journal of physiology.

[28]  H. Plattner,et al.  Lung surfactant protein A (SP-A) enhances serum-independent phagocytosis of bacteria by alveolar macrophages. , 1992, European journal of cell biology.

[29]  C. R. Reed,et al.  Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. , 1991, The Journal of clinical investigation.

[30]  J. Verhoef,et al.  Surfactant protein A is opsonin in phagocytosis of herpes simplex virus type 1 by rat alveolar macrophages. , 1991, The American journal of physiology.

[31]  J. Verhoef,et al.  Pulmonary surfactant protein A enhances the host-defense mechanism of rat alveolar macrophages. , 1990, American journal of respiratory cell and molecular biology.

[32]  J. Wright,et al.  Lung surfactant apoprotein SP-A (26-36 kDa) binds with high affinity to isolated alveolar type II cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[33]  K. Drickamer,et al.  The major lung surfactant protein, SP 28-36, is a calcium-dependent, carbohydrate-binding protein. , 1987, The Journal of biological chemistry.